Biosimilars Market Global Report 2020-30 from the author provides the strategists, marketers and senior management with the critical information they need to assess the global biosimilars market.
Reasons to Purchase
Description:
Where is the largest and fastest growing market for the biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Biosimilars market global report from the author answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider biosimilars market, and compares it with other markets.
Scope
Markets Covered: 1) By Product: Recombinant Non-glycosylated Proteins; Recombinant Glycosylated Proteins; 2) By Types: Human Growth Hormone; Erythropoietin; Monoclonal antibodies; Insulin; Interferon; Granulocyte-Colony Stimulating Factor; Others; 3) By Application: Oncology; Chronic and Autoimmune Diseases; Growth Hormone Deficiency; Infectious Diseases; Others
Companies Mentioned: Pfizer; Amgen; Biocon; Celltrion; Dr. Reddy's Laboratories
Countries: Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA and Australia
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3 working days of order.
Description:
Where is the largest and fastest growing market for the biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Biosimilars market global report from the author answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider biosimilars market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
- The biosimilars market section of the report gives context. It compares the biosimilars market with other segments of the biosimilars market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, biosimilars indicators comparison.
Scope
Markets Covered: 1) By Product: Recombinant Non-glycosylated Proteins; Recombinant Glycosylated Proteins; 2) By Types: Human Growth Hormone; Erythropoietin; Monoclonal antibodies; Insulin; Interferon; Granulocyte-Colony Stimulating Factor; Others; 3) By Application: Oncology; Chronic and Autoimmune Diseases; Growth Hormone Deficiency; Infectious Diseases; Others
Companies Mentioned: Pfizer; Amgen; Biocon; Celltrion; Dr. Reddy's Laboratories
Countries: Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA and Australia
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Table of Contents
1. Executive Summary2. Biosimilars Market Characteristics26. Key Mergers And Acquisitions In The Biosimilars Market27. Biosimilars Market Trends And Strategies28. Biosimilars Market Future Outlook and Potential Analysis
3. Biosimilars Market Size And Growth
4. Biosimilars Market Segmentation
5. Biosimilars Market Regional And Country Analysis
6. Asia-Pacific Biosimilars Market
7. China Biosimilars Market
8. India Biosimilars Market
9. Japan Biosimilars Market
10. Australia Biosimilars Market
11. Indonesia Biosimilars Market
12. South Korea Biosimilars Market
13. Western Europe Biosimilars Market
14. UK Biosimilars Market
15. Germany Biosimilars Market
16. France Biosimilars Market
17. Eastern Europe Biosimilars Market
18. Russia Biosimilars Market
19. North America Biosimilars Market
20. USA Biosimilars Market
21. South America Biosimilars Market
22. Brazil Biosimilars Market
23. Middle East Biosimilars Market
24. Africa Biosimilars Market
25. Biosimilars Market Competitive Landscape And Company Profiles
29. Appendix
Executive Summary
The biosimilars market consists of sales of biosimilars and related services that are used to treat chronic diseases such as diabetes, arthritis, and cancer. Biosimilars are pharmaceuticals that are manufactured using cell lines and offers no clinical difference as compared to biologics. Biosimilars are made once the patent of biologics is expired.The global biosimilars market was worth $7.79 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 31.70% and reach $23.63 billion by 2023.
The biosimilars market covered in this report is segmented by product into recombinant non-glycosylated proteins; recombinant glycosylated proteins. It is also segmented by types into human growth hormone; erythropoietin; monoclonal antibodies; insulin; interferon; granulocyte-colony stimulating factor; others and by application into oncology; chronic and autoimmune diseases; growth hormone deficiency; infectious diseases; others.
The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the biosimilars market. Long working hours, limited physical activity, unhealthy eating and drinking habits contribute to the prevalence of chronic diseases and biosimilars are increasingly used to treat these chronic diseases. Biosimilars activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biosimilars, thus driving the biosimilars market.
The lack of awareness about biosimilars among primary care physicians (PCPs) and specialists limits the growth of the biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, lack of familiarity with biosimilars reduces the likelihood of prescribing the drugs to patients which affects the demand for new biosimilars in the market. For instance, in 2018, according to the PwC’s Health Research Institute, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns included safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the biosimilars market.
Production of new insulin biosimilars is trending in the biosimilars market. The key players operating in the biosimilars market are investing in creating a biosimilar of insulin. This is also promoting competition among various biosimilar manufacturers. For instance, in 2019, Mylan, a U.S-based pharmaceutical company, in partnership with Biocon, an Indian based biopharmaceutical company launched biosimilar insulin glargine named Semglee. Also, in 2019, Oramed Pharmaceuticals, a Jerusalem based pharmaceutical company developed an oral insulin drug named ORMD-0801 to treat type 2 diabetes. Thus, companies in the biosimilars market are investing in the development of insulin biosimilar to gain profits.
In June 2018, Japan-based Fuji Pharma Co., Ltd. acquired a 4.2% stake of Alvotech for US$ 50 million. The acquisition involves Alvotech to develop, manufacture and supply biosimilars and Fuji Pharma will sell the biosimilars in Japan. Alvotech is an Iceland-based biopharmaceutical company.
Major players in the market are Pfizer, Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Boehringer Ingelheim, Elli Lilly and Company, Mylan N.V., Sanofi, and STADA Arzneimittel.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer
- Amgen
- Biocon
- Celltrion
- Dr. Reddy's Laboratories
- Boehringer Ingelheim
- Elli Lilly and Company
- Mylan N.V.
- Sanofi
- STADA Arzneimittel
- Sandoz International
- Samsung Bioepis
- Teva Pharmaceuticals
- Apotex
- AMEGA Biotech S.A.
- Bioton S.A.
- Innovent Biologics, International
- Allergan plc
- BioXpress Therapeutics
- 3SBio
- Intas Biopharmaceuticals
- Lupin, Merck
- Novartis (Sandoz)
- Ratiopharm
- Wockhardt
- Zydus Cadila
- Allergan Plc.
- Hospira International.
- Actavis International.
- Johnson & Johnson
- Roche
Methodology
LOADING...
